 |
Merry
Christmas and a Happy New Year to you all |
| |
Glycosmedia will be published again on Monday
4th January 2010 |
| |
|
|
Glycosmedia
RSS feed |
| |
The latest updates from Glycosmedia are now
available via our new RSS feed (Editor) |
| |
|
|
Effect
of glitazones on the progression of coronary artery disease in
type 2 diabetes patients |
| |
This article reviews the pathophysiology of
atherosclerosis in diabetes, the role that TZDs play in this process
and the imaging trials looking at the progression or regression
of atherosclerosis in patients treated with TZDs (Vascular Health
and Risk Management) |
| |
|
|
Progression
to diabetes in relatives of type 1 diabetic patients: mechanisms
and mode of onset |
| |
In high-risk relatives, ß-cell
glucose sensitivity is impaired and is a strong predictor of diabetes
progression. The time trajectories of plasma glucose are frequently
biphasic, a slow linear increase being followed by a rapid surge,
and are anticipated by a further deterioration of ß-cell glucose sensitivity (Diabetes) |
| |
|
|
Diabetes-Related
Medication-Induced Hypoglycemia |
| |
Following treatment of the episode, it is important
to evaluate for the cause and, if medication related, adjust the
patient’s treatment regimen (Journal of Pharmacy Practice) |
| |
|
|
Six
months of diazoxide treatment at bedtime in newly diagnosed subjects
with type 1 diabetes |
| |
Six months of low-dose diazoxide was without
the side-effects, did not measurably affect insulin production,
but was associated with improved metabolic control (Diabetes Care) |
| |
|
|
Exenatide
Once Weekly Provided Superior Glucose Control Compared to Byetta
in DURATION-5 Study |
| |
Amylin Pharmaceuticals, Eli Lilly and Company
and Alkermes announce positive results from a head-to-head study
comparing exenatide once weekly, an investigational diabetes therapy,
to BYETTA® (exenatide) injection taken twice daily, in patients with type 2 diabetes (PharmaLive) |
| |
|
|
Medical
Management of Hyperglycemia in Type 2 Diabetes |
| |
A Consensus Algorithm for the Initiation and
Adjustment of Therapy (Diabetes Care) |
| |
|
|
GI
Dynamics Gets European Approval |
| |
The company said
it plans to begin selling the device, called the EndoBarrier, in
Europe in the first half of 2010 (Xconomy, USA) |
| |
|
|
Adolescent
type 1 Diabetes cardio-renal Intervention Trial (AdDIT) |
| |
AdDIT will provide important data on the potential
renal and cardiovascular protective effects of ACEI and statins
in high-risk adolescents (BMC Pediatrics) |
| |
|
|
Diabetic
Kidney Disease: A Renin-Angiotensin-Aldosterone System Focused
Review |
| |
At this point in time, the mainstays of therapy
are angiotensin-converting enzyme inhibitors and angiotensin receptor
blockers. More research is currently needed to determine if renin
inhibitors will have an active role in the management of diabetic
kidney disease (Journal of Pharmacy Practice) |
| |
|
|
Aspirin
and diabetes |
| |
Time to rethink aspirin in diabetes? (BMJ) |
| |
|
|
Researchers
Re-Defining the Concept of a Cure for Diabetes |
| |
Much of the discussion surrounding diabetes
concerns day-to-day treatment and how a patient can manage symptoms
and keep the disease from progressing. Rarely does anyone discuss
the possibility of a cure (U.S. Medicine) |
| |
|
|
CNS-targets
in control of energy and glucose homeostasis |
| |
This review summarizes recent findings regarding
the role of the CNS in sensing and transmitting nutritional and
hormonal signals to control energy and glucose homeostasis and
aims to define them as potential novel drug targets for the treatment
of obesity and type 2 diabetes mellitus (Abstract Current Opinion
in Pharmacology - via ScienceDirect) |
| |
|
